Press Release

Granules Life Sciences Receives VAI Classification following US FDA Inspection

Hyderabad, March 31, 2026: Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI).

The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025.

The inspection is now closed, and no regulatory action has been recommended.

Dr. Krishna Prasad Chigurupati, **Chairman and Managing Director, Granules India Limited, said, "While receiving the classification is a step in the right direction, we recognize that quality is not a one-time milestone but an ongoing commitment. It will continue to remain a core pillar of utmost importance across all Granules sites, guiding our actions, investments, and culture every day."**

This development further strengthens Granules India's finished dosage manufacturing capabilities by enabling multi-site manufacturing for the approved products.

END

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, Germany, Canada and Switzerland. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com.

Media Contact:	**Investors Contact:**
Priyanka Chawla Manager- Corporate Communications priyanka.chawla@granulesindia.com	**Chaitanya Tummala** Company Secretary 040-69043614 chaitanya.tummala@granulesindia.com